FDA Would Grant Pediatric Exclusivity For Negative Oncology Studies
Executive Summary
FDA would grant pediatric exclusivity to sponsors despite negative results in either toxicity or efficacy studies, Oncology Drug Products Division Director Richard Pazdur, MD, told the Oncologic Drugs Advisory Committee March 16.
You may also be interested in...
Pediatric Exclusivity Changes Should Be Minimal In Reauthorization - FDA
FDA should consider supporting "wild card" pediatric exclusivity which would allow companies to apply patent extensions to a product of their choice in return for performing needed pediatric research, Oncologic Drugs Advisory Committee member Henry Friedman, MD, Duke University Medical Center, suggested.
Pediatric Exclusivity Changes Should Be Minimal In Reauthorization - FDA
FDA should consider supporting "wild card" pediatric exclusivity which would allow companies to apply patent extensions to a product of their choice in return for performing needed pediatric research, Oncologic Drugs Advisory Committee member Henry Friedman, MD, Duke University Medical Center, suggested.
Alternative Pediatric Oncology Studies Considered As FDA Plans First Request
FDA is considering alternatives to traditional efficacy trials in order to expedite the approval of oncology products for pediatric uses, particularly for diseases with histology similar in adult and pediatric populations.